Your browser doesn't support javascript.
loading
Orthopoxvirus-specific antibodies wane to undetectable levels 1 year after MVA-BN vaccination of at-risk individuals, the Netherlands, 2022 to 2023.
van Leeuwen, Leanne Pm; Shamier, Marc C; Verstrepen, Babs E; Götz, Hannelore M; Schmitz, Katharina S; Akhiyate, Najlae; Wijnans, Koen; Bogers, Susanne; van Royen, Martin E; van Gorp, Eric Cm; Koopmans, Marion Pg; de Vries, Rory D; GeurtsvanKessel, Corine H; Zaeck, Luca M.
Afiliación
  • van Leeuwen LP; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Shamier MC; Travel Clinic, Erasmus University Medical Center Rotterdam, the Netherlands.
  • Verstrepen BE; These authors contributed equally to this work and share first authorship.
  • Götz HM; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Schmitz KS; These authors contributed equally to this work and share first authorship.
  • Akhiyate N; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Wijnans K; Department of Infectious Disease Control, Municipal Public Health Service Rotterdam-Rijnmond (GGD Rotterdam-Rijnmond), Rotterdam, the Netherlands.
  • Bogers S; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • van Royen ME; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • van Gorp EC; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Koopmans MP; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • de Vries RD; Department of Pathology, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • GeurtsvanKessel CH; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Zaeck LM; Travel Clinic, Erasmus University Medical Center Rotterdam, the Netherlands.
Euro Surveill ; 29(38)2024 Sep.
Article en En | MEDLINE | ID: mdl-39301741
ABSTRACT
In response to the mpox outbreak in 2022 and 2023, widespread vaccination with modified vaccinia Ankara-Bavarian Nordic (MVA-BN, also known as JYNNEOS or Imvanex) was initiated. Here, we demonstrate that orthopoxvirus-specific binding and MVA-neutralising antibodies waned to undetectable levels 1 year post vaccination in at-risk individuals who received two doses of MVA-BN administered subcutaneously with an interval of 4 weeks, without prior smallpox or mpox vaccination. Continuous surveillance is essential to understand the impact of declining antibody levels.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Vacunación / Orthopoxvirus / Anticuerpos Antivirales País/Región como asunto: Europa Idioma: En Revista: Euro Surveill Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Vacunación / Orthopoxvirus / Anticuerpos Antivirales País/Región como asunto: Europa Idioma: En Revista: Euro Surveill Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2024 Tipo del documento: Article